‘Eloctate’s extended half-life enables personalized hemophilia treatment’
Eloctate, a coagulation factor treatment with an extended half-life, could help hemophilic patients get customized treatment, an expert said.
Professor Keiji Nogami of the Department of Pediatrics at Nara Medical University shared the latest trend in hemophilia A and B treatment in Japan at the ICKSH 2021 conference on April 1, organized by the Korean Society of Hematology.
In 2020, Sanofi-Aventis Korea’s Eloctate and Alprolix arrived in Korea to suppress and prevent bleeding, bleeding control before and after surgery, and routine preventive therapy to reduce the bleeding frequency in patients with hemophilia A and B, respectively.
Nogami said more Japanese patients were shifting from conventional therapies with the standard half-life to those with extended half-life. “This change makes it possible to get personalized treatment. Physicians should establish an optimal treatment strategy that considers the patient's pharmacokinetic response, joint condition, and lifestyle,” he said.
A coagulation factor therapy with an extended half-life is one of several ways to achieve personalized treatment goals, Nogami said. The new factor treatment with extended half-life offers fewer intravenous administrations and maintains the lowest concentration of the coagulation factor at a higher level than conventional therapies.
“This can reduce the injection burden on pediatric patients and their caregivers and increase compliance with the preventive treatment,” he added.
According to Sanofi-Aventis, Eloctate’s terminal half-life is 19 hours, which is about 1.5 times longer than 12.4 hours of conventional coagulation factor therapy.
Eloctate did not report any formation of antibodies in all three clinical trials (A-LONG, Kids A-LONG, and ASPIRE), and it showed excellent hemostatic effect during surgery.
During 23 surgeries, 21 hemophilic patients received two or fewer administration of Eloctate, and the dose of Eloctate steadily decreased until 14 days after the day of surgery.